Povorcitinib

Generic Name: Povorcitinib

Clinical Trials

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: povorcitinib

First Posted Date: 2025-03-03

Last Posted Date: 2025-05-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 600

Registration Number: NCT06855498

Locations: 🇯🇵
Investigative Site JP008, Nishihara, Japan
🇺🇸
Investigative Site US086, Birmingham, Alabama, United States
🇺🇸
Investigative Site US098, Montgomery, Alabama, United States

and more 313 locations

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Phase 3

Recruiting

Conditions: Prurigo Nodularis

Interventions: Drug: Povorcitinib
Drug: Placebo

First Posted Date: 2024-07-24

Last Posted Date: 2025-05-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 330

Registration Number: NCT06516965

Locations: 🇺🇸
Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
🇺🇸
Investigate Md, Scottsdale, Arizona, United States
🇺🇸
Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas, United States

and more 132 locations

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Phase 3

Recruiting

Conditions: Prurigo Nodularis

Interventions: Drug: Placebo
Drug: Povorcitinib

First Posted Date: 2024-07-24

Last Posted Date: 2025-05-15

Lead Sponsor: Incyte Corporation

Target Recruit Count: 330

Registration Number: NCT06516952

Locations: 🇧🇬
Medconsult Pleven, Pleven, Bulgaria
🇵🇱
Centrum Medyczne Evimed, Warsaw, Poland
🇺🇸
Cahaba Dermatology, Birmingham, Alabama, United States

and more 131 locations

A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants

Phase 1

Active, not recruiting

Conditions: Healthy Participants

Interventions: Drug: Povorcitinib

First Posted Date: 2024-07-17

Last Posted Date: 2024-08-29

Lead Sponsor: Incyte Corporation

Target Recruit Count: 18

Registration Number: NCT06505265

Locations: 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States

A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Participants

Interventions: Drug: Povorcitinib
Drug: Moxifloxacin
Drug: Placebo

First Posted Date: 2024-06-04

Last Posted Date: 2024-07-25

Lead Sponsor: Incyte Corporation

Target Recruit Count: 128

Registration Number: NCT06441318

Locations: 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rosuvastatin
Drug: Metformin
Drug: Digoxin
Drug: Povorcitinib
Drug: Probenecid

First Posted Date: 2024-05-16

Last Posted Date: 2025-02-06

Lead Sponsor: Incyte Corporation

Target Recruit Count: 71

Registration Number: NCT06416800

Locations: 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Povorcitinib
Drug: Levonorgestrel/Ethinyl estradiol

First Posted Date: 2024-04-23

Last Posted Date: 2024-07-03

Lead Sponsor: Incyte Corporation

Target Recruit Count: 24

Registration Number: NCT06380205

Locations: 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Phase 3

Recruiting

Conditions: Hidradenitis Suppurativa (HS)

Interventions: Drug: Povorcitinib

First Posted Date: 2024-01-19

Last Posted Date: 2025-05-11

Lead Sponsor: Incyte Corporation

Target Recruit Count: 960

Registration Number: NCT06212999

Locations: 🇪🇸
Investigative Site ES301, Granada, Spain
🇩🇪
Investigative Site DE301, Frankfurt, Germany
🇩🇪
Investigative Site DE208, Goettingen, Germany

and more 169 locations

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Phase 3

Active, not recruiting

Conditions: NonSegmental Vitiligo

Interventions: Drug: Povorcitinib
Drug: Placebo

First Posted Date: 2023-11-02

Last Posted Date: 2025-03-20

Lead Sponsor: Incyte Corporation

Target Recruit Count: 450

Registration Number: NCT06113471

Locations: 🇨🇦
Research Toronto, Toronto, Ontario, Canada
🇨🇦
Centre de Recherche Dermatologique de Quebec, Quebec City, Quebec, Canada
🇫🇷
Chru Morvan/Chu Brest Hopital Morvan, Brest, France

and more 83 locations

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)

Phase 3

Active, not recruiting

Conditions: NonSegmental Vitiligo

Interventions: Drug: Placebo
Drug: Povorcitinib

First Posted Date: 2023-11-02

Last Posted Date: 2025-03-27

Lead Sponsor: Incyte Corporation

Target Recruit Count: 467

Registration Number: NCT06113445

Locations: 🇺🇸
Revival Research Institute, Llc Dermatology, Troy, Michigan, United States
🇺🇸
Medisearch Clinical Trials, Saint Joseph, Missouri, United States
🇺🇸
Jdr Dermatology Research, Las Vegas, Nevada, United States

and more 97 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy